Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly. Experts at Morrison Foerster share best practices for compliance.

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies ...

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Two universities in North Carolina, known for their expanding research capabilities, have achieved the highest possible classification for doctoral universities. On February 13, East Carolina ...

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

Capsida Biotherapeutics’ CEO Peter Anastasiou shares his thoughts on the current market’s appetite for gene therapies and his company’s plans for 2025.

CEO Peter Anastasiou describes the science behind Capsida’s platform, current pipeline, and why they chose to manufacture in-house.